Hong Kong stock YAOJIE Health-B skyrocketed more than 50% in the afternoon.

Hong Kong-listed pharmaceutical company Yaujya Health-B surged more than 50% in the afternoon, with the stock closing up over 77% on the previous trading day. In terms of news, on September 10, Yaujya Health-B announced that its core product, Tenofig Gefitinib in combination with Fluvi Visqun, has received clinical approval from the National Medical Products Administration for the phase II clinical trial in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative or low-expressed recurrent or metastatic breast cancer who have failed prior treatment.